Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Synergistic Antiviral Activity When Combining AB-423 With Entecavir
IND Filing (or Equivalent) Expected in the Second Half of 2016
VANCOUVER, British Columbia and DOYLESTOWN, Pa., April 14, 2016 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, presented preclinical combination data on its potent core protein/ capsid assembly inhibitor, AB-423, at the European Association for the Study of the Liver (EASL) in Barcelona, Spain.
“We are excited to present data supporting combination of our lead core protein/capsid assembly inhibitor, AB-423, with a nucleoside analog, entecavir (EVT). AB-423 in combination with EVT has shown synergistic antiviral activity in vitro in primary human hepatocytes. Furthermore, AB-423 alone and in combination with entecavir has shown potent in vivo activity in a hydrodynamic injection (HDI) mouse model of HBV,” said Dr. Mark J. Murray, Arbutus’ President and CEO. “We are focused on advancing the development of our proprietary HBV candidates, including AB-423, to enable one or more clinical HBV combination studies in 2017. Additional data from our preclinical combination studies will be presented at upcoming scientific conferences.”
The presentation is titled “In Vitro and In Vivo Antiviral Activities of AB-423 a Potent Small Molecule Inhibitor of Hepatitis B Virus Capsid Assembly”, and a copy of the poster can be accessed by visiting the Investor sections of www.arbutusbio.com and selecting Events and Presentations.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection. Arbutus is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.
Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604.419.3200 Email: [email protected] Helia Baradarani Manager, Investor Relations Phone: 604.419.3200 Email: [email protected] Media Please direct all media inquiries to: [email protected]
